Phibro Animal Health FY26 net income rises 107% to $99.72 million; net sales increase 17% to $1.52 billion

• Phibro Animal Health fiscal 2026 net income rose to $99.7 million; diluted EPS climbed to $2.43.
• Net sales increased 17% to $1.52 billion; operating income jumped 76% to $194.4 million.
• Gross margin widened 2.9 percentage points to 33.8%; interest expense, net increased 28% to $44.4 million.
• Animal Health net sales rose 21% to $1.16 billion, driven partly by $146.1 million of incremental sales from the Zoetis MFA portfolio acquisition.
• Management approved closing the Chicago Heights manufacturing facility, with production shutdown expected in summer 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-101493), on August 26, 2026, and is solely responsible for the information contained therein.